Last reviewed · How we verify
Bovine thrombin
Bovine thrombin is a serine protease that directly converts fibrinogen to fibrin, promoting blood clotting and hemostasis.
Bovine thrombin is a serine protease that directly converts fibrinogen to fibrin, promoting blood clotting and hemostasis. Used for Hemostasis in surgical procedures, Control of bleeding in patients with coagulation disorders, Topical hemostasis in wound management.
At a glance
| Generic name | Bovine thrombin |
|---|---|
| Also known as | Thrombin-JMI |
| Sponsor | Instituto Grifols, S.A. |
| Drug class | Coagulation factor / Hemostatic agent |
| Target | Fibrinogen |
| Modality | Biologic |
| Therapeutic area | Hematology / Hemostasis |
| Phase | FDA-approved |
Mechanism of action
Bovine thrombin is derived from bovine (cow) blood and functions as a coagulation enzyme that catalyzes the final step of the coagulation cascade by cleaving fibrinogen into fibrin monomers, which polymerize to form stable clots. It is used topically or systemically to achieve rapid hemostasis in surgical and bleeding situations where endogenous thrombin production is insufficient or needs to be augmented.
Approved indications
- Hemostasis in surgical procedures
- Control of bleeding in patients with coagulation disorders
- Topical hemostasis in wound management
Common side effects
- Thrombosis / Thromboembolic events
- Allergic reactions
- Fever
- Disseminated intravascular coagulation (DIC)
Key clinical trials
- Goal-Directed Hemostatic Resuscitation Trial in ACLF Induced Coagulopathy (NA)
- Monitoring of Anti-TFPI in Hemophilia
- Efficacy of Platelet-rich-Fibrin Gel in Patients With Chronic Leg Ulcers (EARLY_PHASE1)
- Testing a New Treatment Strategy to Improve Secondary Stroke Prevention for Older Adults: The STROKE75+ Trial (PHASE3)
- A Trial of Intraoperative Fibrin Sealant on Postoperative Recovery After Total Knee Replacement (PHASE4)
- Study of Hemostasis in Patients With Congenital Disorder of Glycosylation
- GATT-Patch Versus TachoSil in Liver Surgery (NA)
- SAFE Study: Safety of aPCC Following Emicizumab Prophylaxis (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Bovine thrombin CI brief — competitive landscape report
- Bovine thrombin updates RSS · CI watch RSS
- Instituto Grifols, S.A. portfolio CI